Analyst Price Targets — OCS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 1, 2026 6:12 pm | — | Robert W. Baird | $38.00 | $14.51 | TheFly | Oculis price target lowered to $38 from $49 at Baird |
| June 1, 2026 11:28 am | — | Guggenheim | $45.00 | $22.71 | TheFly | Oculis price target lowered to $45 from $75 at Guggenheim |
| June 1, 2026 11:28 am | — | Needham | $38.00 | $22.71 | TheFly | Oculis price target lowered to $38 from $46 at Needham |
| June 1, 2026 10:25 am | — | H.C. Wainwright | $26.00 | $22.71 | TheFly | Oculis price target lowered to $26 from $47 at H.C. Wainwright |
| May 20, 2026 8:14 pm | — | Guggenheim | $75.00 | $27.91 | TheFly | Oculis initiated with a Buy at Guggenheim |
| May 12, 2026 4:14 pm | — | H.C. Wainwright | $47.00 | $30.30 | TheFly | Oculis price target raised to $47 from $44 at H.C. Wainwright |
| March 4, 2026 9:46 pm | Annabel Samimy | Stifel Nicolaus | $50.00 | $27.72 | StreetInsider | Oculis Holding AG (OCS) PT Raised to $50 at Stifel |
| December 19, 2025 12:42 pm | Annabel Samimy | Stifel Nicolaus | $40.00 | $20.98 | StreetInsider | Oculis Holding AG (OCS) PT Raised to $40 at Stifel; An 'Under-the-Radar Name' |
| October 8, 2025 11:08 am | — | Chardan Capital | $51.00 | $19.06 | TheFly | Oculis price target raised to $51 from $33 at Chardan |
| October 7, 2025 10:13 am | Yi Chen | H.C. Wainwright | $36.00 | $18.56 | TheFly | Oculis price target raised to $36 from $33 at H.C. Wainwright |
Latest News for OCS
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference.
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for OCS.
Senate Trading
No Senate trades found for OCS.
U.S. House Trading
No House trades found for OCS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.